apl. Prof. Dr. Lucie Heinzerling

Medizinische Fakultät Department of Dermatology

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients (2018) Kirchberger MC, Moreira A, Erdmann M, Schuler G, Heinzerling L Journal article BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma (2018) Walter L, Heinzerling L Journal article, Original article Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports (2018) Schliep S, Agaimy A, Kiesewetter F, Schuler G, Heinzerling L, Cavallaro AJ Journal article Myocarditis in Patients Treated With Immune Checkpoint Inhibitors (2018) Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling L, Sullivan RJ, et al. Journal article MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, et al. Journal article Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders (2018) Kaehler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, et al. Journal article Willingness to pay for a cure of low-risk melanoma patients in Germany (2018) Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, et al. Journal article The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians (2018) Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, et al. Journal article Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy (2018) Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L Journal article Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab (2017) Brueggemann C, Kirchberger MC, Goldinger SM, Weide B, Konrad A, Erdmann M, Schadendorf D, et al. Journal article